News - Otsuka, Neurological

Filter

Current filters:

OtsukaNeurological

Popular Filters

US FDA accepts for review Otsuka and Lundbeck’s sNDA for Abilify Maintena

US FDA accepts for review Otsuka and Lundbeck’s sNDA for Abilify Maintena

30-04-2014

Danish CNS specialist Lundbeck and the US subsidiary of Japan’s Otsuka Pharmaceutical revealed that…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalRegulationUSA

Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

09-04-2014

US biotech firm Alkermes saw its shares spike on Tuesday, after it announced positive top-line results…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyLundbeckNeurologicalOtsukaRegulationResearch

Abilify Maintena cuts hospitalization rates for patients with schizophrenia vs oral antipsychotics

07-04-2014

Danish CNS drug specialist Lundbeck and partner Japanese drugmaker Otsuka Pharmaceutical today announced…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck and Otsuka update on European launch of Abilify Maintena

Lundbeck and Otsuka update on European launch of Abilify Maintena

17-03-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical’s European subsidiary…

Abilify MaintenaEuropeLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Lundbeck and Otsuka’s brexpiprazole shows efficacy in Phase III trial

Lundbeck and Otsuka’s brexpiprazole shows efficacy in Phase III trial

24-01-2014

Danish CNS drug specialist Lundbeck (LUND: CO) and Japanese drug maker Otsuka (TYO: 4768) have revealed…

brexpiprazoleDenmarkLundbeckNeurologicalOtsukaPharmaceuticalResearch

New schizophrenia drug Abilify to lead the market by 2016

New schizophrenia drug Abilify to lead the market by 2016

29-12-2013

Long-acting depot therapy Abilify Maintena (aripiprazole) will become the leading injectable schizophrenia…

AbilifyAbilify MaintenaFinancialGlobalLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Lundbeck and Otsuka to co-develop Alzheimer’s vaccine, Lu AF20513

Lundbeck and Otsuka to co-develop Alzheimer’s vaccine, Lu AF20513

11-12-2013

Danish CNS specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical say they will further expand…

LicensingLu AF20513LundbeckNeurologicalOtsukaPharmaceuticalResearch

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

21-11-2013

Japan’s Otsuka Pharmaceutical (TYO: 4768) and partner Lundbeck (LUN: CO) have received approval from…

Abilify MaintenaAsia-PacificEuropeLundbeckNeurologicalOtsukaPharmaceuticalRegulation

Lundbeck and Otsuka progress new add-on treatment for Alzheimer's

Lundbeck and Otsuka progress new add-on treatment for Alzheimer's

10-10-2013

Denmark-based CNS specialist Lundbeck and partner Japan’s Otsuka Pharmaceutical have announced the…

Lu AE58054LundbeckNeurologicalOtsukaPharmaceuticalResearch

Promising results with Lu AE58054 as add-on to donepezil, in cognitive symptoms of Alzheimer's disease

17-07-2013

Danish CNS specialist Lundbeck (LUN: CO) and Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) presented…

donepezilLu AE58054LundbeckNeurologicalOtsukaPharmaceuticalResearch

UK's NICE plans to recommend Abilify for children with bipolar disorder

10-06-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued new draft…

AbilifyEuropeLundbeckNeurologicalOtsukaPharmaceuticalPricingRegulation

Positive trial results for Otsuka and Lundbeck's Abilify Maintena in schizophrenia

22-05-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578)) and Denmark's Lundbeck (LUND: DC) today (May 22)…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck could get $825 million in further deal with Otsuka, for Alzheimer's drug condidate

26-03-2013

Danish CNS specialist Lundbeck (LUN: CO) has entered a license and development agreement for its Lu AE58054,…

GlobalLicensingLu AE58054LundbeckNeurologicalOtsukaPharmaceutical

Otsuka and Lundbeck expand current Abilify collaboration

07-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Denmark-based CNS specialist Lundbeck (LUND:…

AbilifyAbilify MaintenabrexpiprazoleEuropeLicensingLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia

01-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received…

Abilify MaintenaAlkermesLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Resubmission of aripiprazole NDA accepted; AstraZeneca bond issue

12-09-2012

Danish CNS-focused drugmaker Lundbeck (LUND: DC) and Japanese partner Otsuka Pharmaceutical (TYO: 4668)…

aripiprazole depotAstraZenecaFinancialLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Otsuka files Abilify, first antipsychotic for major depressive disorder in Japan

04-09-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) has filed an additional indication for Abilify (aripiprazole)…

AbilifyAsia-PacificNeurologicalOtsukaPharmaceuticalRegulation

USA: FDA panel votes against Regeneron gout drug; Court upholds Abilify patent

09-05-2012

The US Food and Drug Administration's Arthritis Advisory Committee yesterday voted unanimously (11 to…

AbilifyAnti-Arthritics/RheumaticsArcalystBristol-Myers SquibbLegalNeurologicalNorth AmericaOtsukaPatentsPharmaceuticalRegeneronRegulation

Additional indication for Otsuka’s Abilify in Japan

22-01-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) said last week that it has received new regulatory…

AbilifyAsia-PacificNeurologicalOtsukaPharmaceuticalRegulation

Otsuka Pharma and UCB re-focus collaboration

16-01-2012

Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…

Asia-PacificCimziaImmunologicalsKeppraLicensingNeurologicalOtsukaPharmaceuticalResearchrotigotineUCB

FDA accepts NDA for Lundbeck and Otsuka’s aripiprazole depot formulation

23-11-2011

Danish CNS drug specialist Lundbeck (LUND: DC) and its new partner Japan’s Otsuka Pharmaceutical…

aripiprazole depotLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Lundbeck to pay up to $1.8B to Otsuka under global psychiatric and neuroscience products accord

11-11-2011

Danish CNS drug specialist Lundbeck A/S (LUND: DC) and Japan’s Otsuka Pharmaceutical (TYO: 4768)…

aripiprazole depotLicensingLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Back to top